Lymphocyte transfusion in recent onset type I diabetes mellitus--a one-year follow-up of cell-mediated anti-islet cytotoxicity and C-peptide secretion.

In 19 patients with newly diagnosed Type I diabetes mellitus a single transfusion of 1.9 x 10(9) to 1.5 x 10(10) lymphocytes was performed.

Clinical experience with a radioreceptor assay for TSH-binding inhibiting immunoglobulins (TBII).

The aim of the present study was to evaluate the clinical value of a commercial kit for determination of TBII. Forty-seven of 50 patients with untreated hyperthyroid Graves' disease were TBII positive (sensitivity 94%). TBII was in the normal range in all normal volunteers and in patients with simple goiter, thyroid cancer and in most cases of nonimmunogenic hyperthyroidism (19 of 22).

A follow-up study of cell-mediated cytotoxicity and beta cell function in type I diabetes.

In 20 patients with a newly diagnosed type I diabetes mellitus a cytotoxic effect of blood lymphocytes against beta cells of the pancreas of neonatal rats could be demonstrated. This effect remained nearly unchanged during the first 12 months of control. During the course up to 18 months, the cytotoxicity decreased significantly.

Defect of cellular suppressor function in the pathogenesis of type I diabetes mellitus.

In 29 out of 30 type I diabetic patients the peripheral blood lymphocytes induced an insulin release from isolated rat islets which was regarded as a cytotoxic effect, i.e. a model of beta cell destruction in diabetes mellitus.